British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment
- PMID: 8779124
- PMCID: PMC1090632
- DOI: 10.1136/thx.51.3.238
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment
Abstract
Background: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven.
Methods: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study.
Results: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals.
Conclusions: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.
Comment in
-
Glucocorticosteroids and pulmonary sarcoidosis.Thorax. 1996 Mar;51(3):229-30. doi: 10.1136/thx.51.3.229. Thorax. 1996. PMID: 8779121 Free PMC article. No abstract available.
-
BTS sarcoidosis study.Thorax. 1997 Jan;52(1):102. Thorax. 1997. PMID: 9039252 No abstract available.
-
BTS sarcoidosis study.Thorax. 1997 Jan;52(1):102. Thorax. 1997. PMID: 9039253 No abstract available.
Similar articles
-
A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment.Sarcoidosis Vasc Diffuse Lung Dis. 1997 Mar;14(1):46-56. Sarcoidosis Vasc Diffuse Lung Dis. 1997. PMID: 9186989 Clinical Trial.
-
Early treatment of stage II sarcoidosis improves 5-year pulmonary function.Chest. 2002 Jan;121(1):24-31. doi: 10.1378/chest.121.1.24. Chest. 2002. PMID: 11796428 Clinical Trial.
-
Pharmacotherapeutic management of pulmonary sarcoidosis.Am J Respir Med. 2003;2(4):311-20. doi: 10.1007/BF03256659. Am J Respir Med. 2003. PMID: 14719997 Review.
-
Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis.Eur Respir J. 1995 May;8(5):682-8. Eur Respir J. 1995. PMID: 7656936 Clinical Trial.
-
Clinical aspects of pulmonary sarcoidosis.J S C Med Assoc. 2000 Jan;96(1):9-17. J S C Med Assoc. 2000. PMID: 10670174 Review.
Cited by
-
Interstitial lung disease: progress and problems.Postgrad Med J. 2006 Aug;82(970):494-9. doi: 10.1136/pgmj.2006.046417. Postgrad Med J. 2006. PMID: 16891438 Free PMC article. Review.
-
The importance of PET/CT findings and hematological parameters in prediction of progression in sarcoidosis cases.Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(3):242-250. doi: 10.36141/svdld.v34i3.5299. Epub 2020 Mar 9. Sarcoidosis Vasc Diffuse Lung Dis. 2017. PMID: 32476852 Free PMC article.
-
A clinical approach to the use of methotrexate for sarcoidosis.Thorax. 1999 Aug;54(8):742-6. doi: 10.1136/thx.54.8.742. Thorax. 1999. PMID: 10413729 Free PMC article. Review. No abstract available.
-
Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.Respir Med. 2012 Dec;106(12):1810-3. doi: 10.1016/j.rmed.2012.08.014. Epub 2012 Sep 11. Respir Med. 2012. PMID: 22974830 Free PMC article. Clinical Trial. No abstract available.
-
Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).Lung India. 2020 Jul-Aug;37(4):359-378. doi: 10.4103/lungindia.lungindia_275_20. Lung India. 2020. PMID: 32643655 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources